Peginterferon Alfa-2b API is a pharmaceutical-grade PEGylated recombinant interferon alfa-2b developed for the treatment of chronic hepatitis B, chronic hepatitis C, malignant melanoma, and other viral and immune-mediated disorders. PEGylation prolongs the drug's half-life, allowing sustained therapeutic activity and reduced dosing frequency compared to conventional interferon alfa.
Peginterferon Alfa-2b exerts antiviral, antiproliferative, and immunomodulatory effects by activating intracellular signaling pathways that inhibit viral replication and enhance immune responses.
Manufactured under WHO-GMP-certified biopharmaceutical facilities, our Peginterferon Alfa-2b API is produced using advanced recombinant DNA and PEGylation technologies to ensure exceptional purity, biological activity, stability, and batch-to-batch consistency. Every batch undergoes rigorous quality testing and is supplied with complete documentation, including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and Product Specifications.
Peginterferon Alfa-2b API is used in injectable biopharmaceutical formulations for chronic hepatitis B, chronic hepatitis C, melanoma, and other immune-mediated disorders.
It activates antiviral and immune signaling pathways, suppresses viral replication, enhances immune cell activity, and provides prolonged therapeutic action through PEGylation.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Peginterferon Alfa-2b API in commercial quantities for pharmaceutical and biopharmaceutical manufacturing worldwide.
Get Bulk Quote via WhatsApp